Drug Trial Radar · NCT00617695
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Last checked: Nov 20, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
247
Actual
Start
Sep 2003
Primary completion
Not stated
Study completion Oct 2004
Sponsor
- Lead sponsor
- Impax Laboratories, LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
Conditions
- Migraine
Interventions
ZolmitriptanDrug
5mg nasal spray
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Headache response and pain-free response to treatmentTime frame: 15 minutes, 30 minutes, 45 minutes, 1.5 hours and 2 hours after randomized treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.